Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Disease mechanisms

Topic: Brain proteins, microglia and lab models

Plain-language summary

Neurogranin levels were significantly reduced in MTLE-HS patients as compared to FLE patients and healthy controls but were not correlated with any of the clinical and cognitive variables. Both FLE and MTLE-HS patients with treatment resistance showed significantly reduced neurogranin levels. Our results suggest that MTLE-HS patients suffer from reduced synaptic protein production rather than increased synaptic breakdown. Reduction of neurogranin is associated with resistance to anti-epileptic treatment implying the role of this protein in the control of seizures. Neurogranin might serve as a biomarker for monitorization of seizure activity in focal epilepsies.

What this study adds

Evidence grade: Low

The record lists 51 participants. In this preliminary study of people with focal epilepsy, neurogranin levels were reduced in patients with treatment resistance, suggesting the protein may serve as a biomarker for monitoring seizure activity. The study is about epilepsy, not Alzheimer's disease, and does not test any treatment for Alzheimer's.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Şişman, A. B., Merve, S., Koral, G., Bayar, M. D., Yildiz, O., Mutlu, A., et al. (2025). Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study. Ideggyógyászati Szemle. https://doi.org/10.18071/isz.78.0163

Vancouver

Şişman AB, Merve S, Koral G, Bayar MD, Yildiz O, Mutlu A, et al. Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study. Ideggyógyászati Szemle. 2025. doi:10.18071/isz.78.0163. PMID: 40476457.

BibTeX

@article{sisman2025-40476457,
  author  = {Şişman, Aysel Büşra and Merve, Savaş and Koral, Gizem and Bayar, Muhammet Duran and Yildiz, Oğuz and Mutlu, Aytül and Yılmaz, Vuslat and Tüzün, Erdem and others},
  title   = {{Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study}},
  journal = {Ideggyógyászati Szemle},
  year    = {2025},
  doi     = {10.18071/isz.78.0163},
  pmid    = {40476457},
  url     = {https://doi.org/10.18071/isz.78.0163}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this preliminary study of people with focal epilepsy, neurogranin levels were reduced in patients with treatment resistance, suggesting the protein may serve as a biomarker for monitoring seizure activity. The study is about epilepsy, not Alzheimer's disease, and does not test any treatment for Alzheimer's.

Study details

How this study scored 33/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 1 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 33 of 100.33 of 100 points earned67 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Ideggyógyászati Szemle)
Journal's citation record 0 / 4 Ideggyógyászati Szemle: journal h-index 15 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 51 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.3 citations a year over 3 year(s) since 2025
Impact for its field and year 1 / 6 Cited 0.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Özlem Çokar: h-index 12 (OpenAlex, whole career)
Institution's track record 0 / 3 Istanbul University: institution h-index 441 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40476457)
Free to read 0 / 2 Behind a paywall — scores zero
Total 33 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Disease mechanisms from nearby years

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Disease mechanisms

See all studies in Disease mechanisms →